Hemispherectomy: The Full Half of the Glass

Longitudinal Seizure Outcome and Prognostic Predictors After Hemispherectomy in 170 Children.


OBJECTIVE: Data on longitudinal seizure outcome after hemispherectomy in children are limited. This study explores the posthemispherectomy longitudinal seizure outcome and its predictors. METHODS: We reviewed 186 consecutive children who underwent hemispherectomy between 1997 and 2009 at our center. Clinical, EEG, imaging, and surgical data were collected. Seizure outcome data were collected via a structured questionnaire by contacting families (n = 125) or from the medical records at last follow-up (n = 58). RESULTS: Of 186 patients, 3 were lost to follow-up; 13 seizure-free patients with new-onset nonepileptic spells were excluded. Perioperative complications were not collected. There was no mortality. At a mean follow-up of 5.3 years (±3.3 years), 112 of 170 children (66%) were seizure-free (Engel class 1a). In 58 patients with seizure recurrence, 8 had late remission and 16 had >90% reduction. Overall, at last follow-up, 136 patients (80%) were either seizure-free or had major improvement. Using survival analysis, the estimated probability of seizure freedom after hemispherectomy was 78% [95% confidence interval (CI) = 75%-81%] at 6 months, 76% (95% CI = 73%-79%) at 1 year, 71% (95% CI = 68%-74%) at 2 years, and 63% (95% CI = 59%-67%) at 5 years. On multivariate analysis, bilateral PET abnormalities (risk ratio = 2.53, 95% CI = 1.02-5.85) and acute postoperative seizures (risk ratio = 7.03, 95% CI = 3.07-15.9) independently predicted seizure recurrence. CONCLUSIONS: The long-term seizure-free rates after hemispherectomy remained stable at 63% at 5 years and beyond. This study will assist in better candidate selection for hemispherectomy, presurgical counseling, and early identification of surgical failures.

Commentary

Hemispherectomy was introduced by Walter Dandy in 1928 for removal of a right hemispheric glioma (1) but was pioneered for use in catastrophic epilepsy by McKenzie a decade later (2). The procedure was abandoned for years due to its morbidity and mortality but was repopularized in 1950 by Krynauw, who used it to treat infantile hemiplegia (3). The techniques of hemispherectomy then underwent many changes over the years, with Rasmussen developing the notion of functional hemispherectomy in 1974, which in turn, underwent further modifications with very low mortality rates (4). Hemispherectomy is now a well-established procedure for holohemispheric drug-resistant epilepsies, constituting 20–40% of all pediatric epilepsy surgeries at some centers (5). These epilepsies are often associated with hemimegalencephaly, porencephaly, malformations of cortical development, Sturge–Weber syndrome, infantile hemiplegia, and Rasmussen’s encephalitis. Other etiologies that may be appropriate for hemispherectomy include stroke, trauma, arteriovenous malformations, hemiatrophy, and tuberous sclerosis. Candidates for hemispherectomy typically have hemiparesis and other baseline neurologic deficits that lateralize to the epileptic hemisphere.

Furthermore, due to its overall long-term cognitive, behavioral, and psychosocial benefits, this surgery is also recommended in individuals who have retained some functions in the diseased hemisphere, especially when surgery is performed early. Such improvements often outweigh any worsening of motor impairments (6). Additionally, the young brain has remarkable plasticity that facilitates reorganization of eloquent functions. This is exemplified by a child whose baseline language fMRI lateralized to the left, but after left hemispherectomy, the fMRI showed evidence of later reorganization of language functions to the right (7).

Moosa et al. studied 186 children who underwent hemispherectomy by a single surgeon (8), with the goal of assessing longitudinal outcome of seizure freedom rates by survival analysis, and predictors of seizure outcome by proportional hazard modeling. They excluded 3 patients due to loss of follow-up and 13 due to emergence of non-epileptic paroxysmal events. Of the remaining 170 patients, 112 (66%) were seizure free after a mean follow-up period of 5.3 (± 3.3) years. Of those who experienced seizure recurrence, 8 patients achieved late remission and 16 achieved more than 90% reduction of seizure frequency, increasing the number of patients achieving major improvement to 136 patients (80%). In addition, the authors mention that the 13 excluded subjects with nonepileptic events also experienced resolution of their habitual seizures. Interestingly, 76 (67%) of the seizure-free subjects were not on antiepileptic medications. Survival analysis found a seizure
freedom rate of 86% at 3 months, dropping to 63% at 5 years or beyond.

Univariate analysis found that acute postoperative seizures (defined as seizures occurring within one week of the surgery), non-lateralizing ictal EEG, and bilateral PET abnormalities predicted seizure recurrence. Of these, bilateral PET abnormalities and acute postoperative seizures independently predicted seizure recurrence on multivariate Cox proportional hazard analysis, with the risk of seizure recurrence being 7 times higher in patients with acute postoperative seizures. Moreover, 54% of all patients who failed hemispherectomy experienced their seizure recurrence within 4 postoperative months. Of importance, there were no differences between seizure-free and seizure-recurrence groups with regards to preoperative seizure frequency, localization of preoperative interictal epileptiform discharges, etiology, baseline motor deficits, or brain MRI findings in the contralateral hemisphere. The authors concluded that metabolic abnormalities in the contralateral hemisphere on PET may be more predictive of seizure outcome than contralateral MRI abnormalities. Some of the subjects in this cohort had undergone previous surgery, and hemispherectomy resulted in seizure freedom in 35% of patients who had failed previous hemispherectomy and in 78% of those who had failed focal resection.

The outcome reported in this study is in line with previous results. Across studies, seizure reduction rates after hemispherectomy have ranged between 50% and 92%, with very low mortality rates (4). However, this study’s peculiar strengths lie in its large sample size of 170 subjects and in the duration of follow-up: Almost half the subjects in this cohort had a follow-up of at least 5 years, with more than one-fifth followed up for at least 8 years. This facilitated conduction of a survival analysis that can be very helpful when counseling patients and their families about chances of continued seizure freedom as a function of time. The large cohort also facilitated answering chronic questions about the significance of various risk factors for seizure recurrence. For example, previous studies often correlated the outcome with etiology (4); this was not supported by the study discussed here.

Although this is a single-center experience, the concordance of the conclusions with data from other centers confirms the great utility of hemispherectomy in intractable holohemispheric epilepsy. For example, other authors have similarly found that acute postoperative seizures (also defined as seizures in the first postoperative week) are associated with seizure recurrence (9, 10) and that such seizures should encourage early evaluation of surgical failure. In addition, the current results confirm known findings that bilateral ictal EEG does not exclude patients from hemispherectomy (11) and, even more importantly, that contralateral MRI findings do not contraindicate surgery (5). Future studies should focus more on motor and cognitive outcomes after hemispherectomy in light of the duration of epilepsy, age at surgery, presurgical functioning, and etiology, in addition to postoperative seizure outcome. A better understanding of outcome predictors will help plan more adequate postsurgical rehabilitation. Finally, a recent nationwide pediatric inpatient database analysis concluded that the annual performance of hemispherectomy is still infrequent, likely due to the few tertiary high-volume centers that can perform the procedure (4). Perhaps the positive outcomes reported in this study will encourage increased consideration of hemispherectomy in epilepsy centers.

by Mohamad Koubeissi, MD

References

Instructions
The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in four parts.

1. **Identifying information.**
   Enter your full name. If you are NOT the main contributing author, please check the box “no” and enter the name of the main contributing author in the space that appears. Provide the requested manuscript information.

2. **The work under consideration for publication.**
   This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking “No” means that you did the work without receiving any financial support from any third party – that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check “Yes”. Then complete the appropriate boxes to indicate the type of support and whether the payment went to you, or to your institution, or both.

3. **Relevant financial activities outside the submitted work.**
   This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. For example, if your article is about testing an epidermal growth factor receptor (DGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

   Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work’s sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

   For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

4. **Other relationships**
   Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.
Section #1 Identifying Information

1. Today’s Date: 6/12/2012

2. First Name: Mohamad Last Name: Koubeissi Degree: MD

3. Are you the Main Assigned Author? ☒ Yes ☐ No

If no, enter your name as co-author:

4. Manuscript/Article Title: Hemispherectomy: the Full Half of the Glass

5. Journal Issue you are submitting for: 13.5

Section #2 The Work Under Consideration for Publication

Did you or your institution at any time receive payment or services from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Grant</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consulting fee or honorarium</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Support for travel to meetings for the study or other purposes</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Fees for participating in review activities such as data monitoring boards, statistical analysis, end point committees, and the like</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Payment for writing or reviewing the manuscript</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Provision of writing assistance, medicines, equipment, or administrative support.</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Other</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts on this study.
** Use this section to provide any needed explanation.
Section #3 Relevant financial activities outside the submitted work.
Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the “Add” box. You should report relationships that were present during the 36 months prior to submission.

Complete each row by checking “No” or providing the requested information. If you have more than one relationship just add rows to this table.

<table>
<thead>
<tr>
<th>Type of relationship (in alphabetical order)</th>
<th>No</th>
<th>Money Paid to You</th>
<th>Money to Your Institution*</th>
<th>Name of Entity</th>
<th>Comments**</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Board membership</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2. Consultancy</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3. Employment</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4. Expert testimony</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5. Grants/grants pending</td>
<td>☐</td>
<td>The authors is a Spitz scholar and has received Grants from the Coulter Foundation and Medtronic</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6. Payment for lectures including service on speakers bureaus</td>
<td>☐</td>
<td>From UCB, Cyberonics and Pfizer</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Payment for manuscript preparation</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8. Patents (planned, pending or issued)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9. Royalties</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10. Payment for development of educational presentations</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11. Stock/stock options</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12. Travel/accommodations/meeting expenses unrelated to activities listed.**</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13. Other (err on the side of full disclosure)</td>
<td>☒</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* This means money that your institution received for your efforts.
** For example, if you report a consultancy above there is no need to report travel related to that consultancy on this line.

Section #4 Other relationships
Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?

☑ No other relationships/conditions/circumstances that present a potential conflict of interest.
☐ Yes, the following relationships/conditions/circumstances are present:

Thank you for your assistance.
Epilepsy Currents Editorial Board